Score Overview
PeriodNet IncomeRevenueScoreGrowthTrendConsistencyGrowthTrendConsistency
1 Year
—
-5.87%
Shrank
—
—
—
—
1 Year
Score—
Net Growth-5.87%
Net TrendShrank
Net Income Consistency—
Rev Growth—
Rev Trend—
Revenue Consistency—
5 Years
—
-156.95%
40%
—
36x
—
—
5 Years
Score—
Net Growth-156.95%
Net Trend40%
Net Income Consistency—
Rev Growth36x
Rev Trend—
Revenue Consistency—
Explore the 2021 public Archive ranking →
Where Crescent Biopharma, Inc. has ranked, year by year
Measure
Not enough ranking history to display a chart
This chart needs at least two years of available HDB Score rankings on 10 years of fundamentals. CBIO does not have enough ranked years in the public Archive through 2021.
More recent Archive years are available with Membership. Coverage varies by company and measure.
Net Income x Stock Price
Historical Returns
| Period | Price | Return |
|---|---|---|
Last Price2026-10-23 | $ 12.82 | — |
1 Year2025-10-23 | $ 12.79 | 0.23% |
5 Years2021-10-22 | $ 196.00 | -93.46% |
10 Years2016-10-21 | $ 643.00 | -98.01% |
All Time2014-01-10 | $ 901.00 | -98.58% |
| Period | Last Price2026-10-23 | 1 Year2025-10-23 | 5 Years2021-10-22 | 10 Years2016-10-21 | All Time2014-01-10 |
|---|---|---|---|---|---|
| Price | $ 12.82 | $ 12.79 | $ 196.00 | $ 643.00 | $ 901.00 |
| Return | — | 0.23% | -93.46% | -98.01% | -98.58% |
Prices are split & dividend adjusted. All values are reported in USD.
Fundamental Data
Reported in USD
| Year | |||
|---|---|---|---|
| TTM | $ 42M | -$ 162M | $ 171M |
| 2025 | -$ 153M | $ 213M | |
| 2024 | -$ 48M | $ 34M | |
| 2023 | -$ 36M | $ 41M | |
| 2022 | -$ 46M | $ 47M | |
| 2021 | $ 1M | -$ 63M | $ 90M |
| 2020 | -$ 51M | $ 137M | |
| 2019 | -$ 54M | $ 158M | |
| 2018 | -$ 48M | $ 209M | |
| 2017 | -$ 33M | $ 123M | |
| 2016 | $ 18.5K | -$ 31M | $ 40M |
| 2015 | $ 20M | -$ 12M | $ 46M |
| IPO2014 | $ 15M | -$ 11M | $ 55M |
Crescent Biopharma, Inc. fundamental performance
Across Crescent Biopharma, Inc.'s full reported history, from 2014 to 2025, net income went from -$ 11M to -$ 153M. Revenue increased in 50% of the years measured; net income in 25%.
Membership
Explore CBIO with current data
The public Archive runs through 2021. Membership adds recent and current rankings.
- Recent and current rankings across 5,112 companies
- Compare companies with the latest data
- Track your research shortlist in a portfolio
